Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.

Human mutation - 1 Nov 2002

Phelan Catherine M, Kwan Elaine, Jack Elaine, Li Song, Morgan Cindy, Aubé Jennifer, Hanna Danielle, Narod Steven A

Abstract excerpt

The 185delAG and 5382insC founder mutations account for the majority of mutations identified in BRCA1 in Ashkenazi Jewish breast and breast-ovarian cancer families. Few non-founder BRCA1 mutations have been identified to date in these families. We initially screened a panel of 245 Ashkenazi Jewish breast-ovarian cancer families with an affected proband and at least one other case of breast or ovarian cancer for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Family Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Founder Effect

Share to Gene Frequency

Share to Genes, BRCA1

Share to Ovarian Neoplasms

Share to Pedigree

Source

Identifiers

PMID: 12402332
DOI: 10.1002/humu.10123

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.PMID 12402332Read ↗

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.Semantic proximity Read ↗

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.Semantic proximity Read ↗

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.Semantic proximity Read ↗

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.Semantic proximity Read ↗

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.Semantic proximity Read ↗

Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.Semantic proximity Read ↗

A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.Semantic proximity Read ↗

An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.Semantic proximity Read ↗

Identifying Ashkenazi Jewish <i>BRCA1/2</i> founder variants in individuals who do not self-report Jewish ancestrySemantic proximity Read ↗

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.